150 related articles for article (PubMed ID: 29223415)
1. [Psychological impact of prostate cancer on patients receiving a 6-month androgen deprivation therapy].
de la Taille A; Mardoyan S; Lafaye A
Prog Urol; 2018 Jan; 28(1):32-38. PubMed ID: 29223415
[TBL] [Abstract][Full Text] [Related]
2. [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study].
Ouzaid I; Rouprêt M
Prog Urol; 2011 Nov; 21(12):866-74. PubMed ID: 22035913
[TBL] [Abstract][Full Text] [Related]
3. A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels.
Venderbos LD; van den Bergh RC; Roobol MJ; Schröder FH; Essink-Bot ML; Bangma CH; Steyerberg EW; Korfage IJ
Psychooncology; 2015 Mar; 24(3):348-54. PubMed ID: 25138075
[TBL] [Abstract][Full Text] [Related]
4. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
[TBL] [Abstract][Full Text] [Related]
5. [Quality of life following endocrine therapy for advanced prostate cancer: a comparative study between LH-RH agonist 1-month depot and 3-month depot].
Namiki S; Ishidoya S; Saito S; Mitsukawa S; Suzuki Y; Numata I; Arai Y
Nihon Hinyokika Gakkai Zasshi; 2008 Jul; 99(5):631-7. PubMed ID: 18697469
[TBL] [Abstract][Full Text] [Related]
6. Health-Related Quality of Life in 536 Long-Term Prostate Cancer Survivors after Treatment with Leuprorelin Acetate: A Combined Retrospective and Prospective Analysis.
Hammerer PG; Wirth MP;
Urol Int; 2018; 100(1):72-78. PubMed ID: 29183006
[TBL] [Abstract][Full Text] [Related]
7. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
[TBL] [Abstract][Full Text] [Related]
8. Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy.
Richard PO; Fleshner NE; Bhatt JR; Hersey KM; Chahin R; Alibhai SM
BJU Int; 2015 Nov; 116(5):744-52. PubMed ID: 24684534
[TBL] [Abstract][Full Text] [Related]
9. The current status of hormone treatment for prostate cancer patients in Korean real-world practice: a multi-institutional observational study.
Kim JK; Kim JJ; Gang TW; Kwon TK; Kim HS; Park SC; Park JS; Park JY; Yoon SJ; Jeon YS; Cho JS; Joo KJ; Hong SH; Byun SS;
Asian J Androl; 2019; 21(2):115-120. PubMed ID: 30604695
[TBL] [Abstract][Full Text] [Related]
10. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations.
Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Oya M
J Med Econ; 2017 Nov; 20(11):1155-1162. PubMed ID: 28758810
[TBL] [Abstract][Full Text] [Related]
11. Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma.
Fornara P; Jocham D
Urol Int; 1996; 56 Suppl 1():18-22. PubMed ID: 8776813
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer.
Tavlarides AM; Ames SC; Diehl NN; Joseph RW; Castle EP; Thiel DD; Broderick GA; Parker AS
Psychooncology; 2013 Jun; 22(6):1328-35. PubMed ID: 22855322
[TBL] [Abstract][Full Text] [Related]
13. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance.
Parker PA; Davis JW; Latini DM; Baum G; Wang X; Ward JF; Kuban D; Frank SJ; Lee AK; Logothetis CJ; Kim J
BJU Int; 2016 Mar; 117(3):469-77. PubMed ID: 25714186
[TBL] [Abstract][Full Text] [Related]
14. The effects of long-term androgen deprivation therapy on penile length in patients with prostate cancer: a single-center, prospective, open-label, observational study.
Park KK; Lee SH; Chung BH
J Sex Med; 2011 Nov; 8(11):3214-9. PubMed ID: 21699669
[TBL] [Abstract][Full Text] [Related]
15. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study.
Potosky AL; Knopf K; Clegg LX; Albertsen PC; Stanford JL; Hamilton AS; Gilliland FD; Eley JW; Stephenson RA; Hoffman RM
J Clin Oncol; 2001 Sep; 19(17):3750-7. PubMed ID: 11533098
[TBL] [Abstract][Full Text] [Related]
16. Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report.
Chang JI; Bucci J
J Med Case Rep; 2016 Nov; 10(1):323. PubMed ID: 27836000
[TBL] [Abstract][Full Text] [Related]
17. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
[TBL] [Abstract][Full Text] [Related]
18. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
Ulloa EW; Salup R; Patterson SG; Jacobsen PB
Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
[TBL] [Abstract][Full Text] [Related]
20. Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study.
Dale W; Hemmerich J; Bylow K; Mohile S; Mullaney M; Stadler WM
J Clin Oncol; 2009 Apr; 27(10):1557-63. PubMed ID: 19255325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
